文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

埃莫德普赛与阿苯达唑在坦桑尼亚奔巴岛青少年和成人钩虫感染中的疗效与安全性:一项双盲、优效性、2b期随机对照试验

Efficacy and safety of emodepside compared with albendazole in adolescents and adults with hookworm infection in Pemba Island, Tanzania: a double-blind, superiority, phase 2b, randomised controlled trial.
PubMed 文献 · Lancet · 2024-01-01

在坦桑尼亚奔巴岛开展双盲优效性2b期随机对照试验,293例钩虫感染者分别接受埃莫德普赛30 mg或阿苯达唑400 mg治疗。埃莫德普赛组治愈率96.6%,显著高于阿苯达唑组81.2%(OR 0.14,95%CI 0.04-0.35;p=0.0001),但不良事件更常见,未见严重不良事件。

要点

  • 埃莫德普赛30 mg治疗钩虫感染的治愈率为96.6%,显著高于阿苯达唑400 mg的81.2%。
  • 埃莫德普赛组最常见不良事件为服药后3小时视力模糊(39%),不良事件多为轻度(93%)。
  • 埃莫德普赛组不良事件频率高于阿苯达唑组,需权衡高效与不良事件增加。

核心结论

  • 该2b期临床试验证实埃莫德普赛对钩虫感染具有高疗效,巩固其作为有前景的抗蠕虫候选药物的地位。
  • 观察到的安全性事件总体为轻度,但需权衡强效结局与相较阿苯达唑增加的不良事件频率。

研究设计与样本

  • 双盲、优效性、2b期随机对照临床试验,比较埃莫德普赛与阿苯达唑。
  • 从坦桑尼亚奔巴岛四个流行村和三所中学招募12-60岁钩虫阳性者,需四次Kato-Katz厚涂片虫卵计数≥48个/克且至少两张涂片钩虫卵>1个。
  • 共筛查1609人,治疗293人:阿苯达唑组147人,埃莫德普赛组146人;按感染强度分层。
  • 埃莫德普赛组接受6片5 mg片剂(合计30 mg)加1片安慰剂;阿苯达唑组接受1片400 mg片剂加6片安慰剂。
  • 治疗后3小时、24小时、48小时和14-21天报告不良事件;试验注册号NCT05538767。

主要发现

  • 埃莫德普赛组观察治愈率96.6%,显著高于阿苯达唑组81.2%(比值比0.14,95%CI 0.04-0.35;p=0.0001)。
  • 埃莫德普赛组最常见不良事件为治疗后3小时视力模糊(146例中57例,39%)。
  • 埃莫德普赛组其他常见不良事件包括治疗后24小时视力模糊(55例,38%)、3小时头痛(55例,38%)和头晕(43例,30%)。
  • 埃莫德普赛组319例不良事件中298例(93%)为轻度;阿苯达唑组最常见为3小时头痛(147例中27例,18%)和头晕(14例,10%)。
  • 未报告严重不良事件。

关键数值与推荐

  • 治愈率定义:治疗前钩虫阳性、治疗后转为钩虫阴性。
  • 埃莫德普赛组治愈率96.6% vs 阿苯达唑组81.2%(比值比0.14,95%CI 0.04-0.35;p=0.0001)。
  • 埃莫德普赛组3小时视力模糊57/146(39%),24小时视力模糊55/146(38%),3小时头痛55/146(38%),3小时头晕43/146(30%)。
  • 阿苯达唑组3小时头痛27/147(18%),3小时头晕14/147(10%)。
  • 埃莫德普赛组不良事件319例中轻度298例(93%);未报告严重不良事件。

临床怎么用

  • 作者认为该2b期试验证实埃莫德普赛对钩虫感染的高疗效,巩固其作为有前景的抗蠕虫候选药物的地位。
  • 作者指出尽管安全性事件总体为轻度,需权衡强效结局与相较阿苯达唑增加的不良事件频率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human hookworm is a cause of enormous global morbidity. Current treatments have insufficient efficacy and their extensive and indiscriminate distribution could also result in drug resistance. Therefore, we tested the efficacy and safety of emodepside, a strong anthelmintic candidate that is currently undergoing clinical development for onchocerciasis and soil-transmitted helminth infections. METHODS: We conducted a double-blind, superiority, phase 2b, randomised controlled clinical trial comparing emodepside and albendazole. Participants in the emodepside group received six 5 mg tablets of emodepside (totalling 30 mg) and one placebo; participants in the albendazole group received one 400 mg tablet of albendazole and six placebos. Participants were recruited from four endemic villages and three secondary schools in Pemba Island, Tanzania. Participants aged 12-60 years were eligible for treatment if they were positive for hookworm infection, and they had 48 or more eggs per gram from four Kato-Katz thick smears and at least two slides had more than one hookworm egg present. Participants' treatment allocation was stratified by infection intensity and efficacy was measured by cure rate: participants who were hookworm positive and became hookworm negative after treatment. Adverse events were reported at 3 h, 24 h, 48 h, and 14-21 days post-treatment. The trial is registered at ClinicalTrials.gov, NCT05538767. FINDINGS: From Sept 15 to Nov 8, 2022, and from Feb 15 to March 15, 2023, 1609 individuals were screened for hookworm. Of these, 293 individuals were treated: 147 with albendazole and 146 with emodepside. Emodepside demonstrated superiority, with an observed cure rate against hookworm of 96·6%, which was significantly higher compared with albendazole (cure rate 81·2%, odds ratio 0·14, 95% CI 0·04-0·35; p=0·0001). The most common adverse event in the emodepside treatment group was vision blur at 3 h after treatment (57 [39%] of 146). Other common adverse events were vision blur at 24 h after treatment (55 [38%]), and headache and dizziness at 3 h after treatment (55 [38%] for headache and 43 [30%] for dizziness). In the emodepside treatment group, 298 (93%) of the 319 adverse events were mild. The most commonly reported adverse events in the albendazole treatment group were headache and dizziness at 3 h after treatment (27 [18%] of 147 for headache and 14 [10%] for dizziness). No serious adverse events were reported. INTERPRETATION: This phase 2b clinical trial confirms the high efficacy of emodepside against hookworm infections, solidifying emodepside as a promising anthelmintic candidate. However, although the observed safety events were generally mild in severity, considerations must be made to balance the strong efficacy outcomes with the increased frequency of adverse events compared with albendazole. FUNDING: European Research Council.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Taylor L, Ahmada AA, Ali MS, et al. Efficacy and safety of emodepside compared with albendazole in adolescents and adults with hookworm infection in Pemba Island, Tanzania: a double-blind, superiority, phase 2b, randomised controlled trial. Lancet. 2024. PMID: 39153818. doi:10.1016/S0140-6736(24)01403-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。